262 related articles for article (PubMed ID: 15065530)
1. [Comparative effectiveness of the antisecretory action of rabeprazole and esomeprazole in people with rapid metabolism of proton pump inhibitors].
Morozov SV; Tsodikova OM; Isakov VA; Gushchin AE; Shipulin GA
Eksp Klin Gastroenterol; 2003; (6):58-63, 154. PubMed ID: 15065530
[TBL] [Abstract][Full Text] [Related]
2. Comparison of the effects of esomeprazole 40 mg, rabeprazole 20 mg, lansoprazole 30 mg, and pantoprazole 40 mg on intragastrıc pH in extensive metabolizer patients with gastroesophageal reflux disease.
Çelebi A; Aydın D; Kocaman O; Konduk BT; Şentürk Ö; Hülagü S
Turk J Gastroenterol; 2016 Sep; 27(5):408-414. PubMed ID: 27782887
[TBL] [Abstract][Full Text] [Related]
3. Effects of rabeprazole, lansoprazole and omeprazole on intragastric pH in CYP2C19 extensive metabolizers.
Saitoh T; Fukushima Y; Otsuka H; Hirakawa J; Mori H; Asano T; Ishikawa T; Katsube T; Ogawa K; Ohkawa S
Aliment Pharmacol Ther; 2002 Oct; 16(10):1811-7. PubMed ID: 12269976
[TBL] [Abstract][Full Text] [Related]
4. CYP2C19 genotype status and intragastric pH during dosing with lansoprazole or rabeprazole.
Adachi K; Katsube T; Kawamura A; Takashima T; Yuki M; Amano K; Ishihara S; Fukuda R; Watanabe M; Kinoshita Y
Aliment Pharmacol Ther; 2000 Oct; 14(10):1259-66. PubMed ID: 11012469
[TBL] [Abstract][Full Text] [Related]
5. A comparison of the acid-inhibitory effects of esomeprazole and rabeprazole in relation to pharmacokinetics and CYP2C19 polymorphism.
Hunfeld NG; Touw DJ; Mathot RA; van Schaik RH; Kuipers EJ
Aliment Pharmacol Ther; 2012 Apr; 35(7):810-8. PubMed ID: 22324425
[TBL] [Abstract][Full Text] [Related]
6. Review article: relationship between the metabolism and efficacy of proton pump inhibitors--focus on rabeprazole.
Horn J
Aliment Pharmacol Ther; 2004 Nov; 20 Suppl 6():11-9. PubMed ID: 15496214
[TBL] [Abstract][Full Text] [Related]
7. Gastric acid control with esomeprazole, lansoprazole, omeprazole, pantoprazole, and rabeprazole: a five-way crossover study.
Miner P; Katz PO; Chen Y; Sostek M
Am J Gastroenterol; 2003 Dec; 98(12):2616-20. PubMed ID: 14687806
[TBL] [Abstract][Full Text] [Related]
8. Different dosage regimens of rabeprazole for nocturnal gastric acid inhibition in relation to cytochrome P450 2C19 genotype status.
Sugimoto M; Furuta T; Shirai N; Kajimura M; Hishida A; Sakurai M; Ohashi K; Ishizaki T
Clin Pharmacol Ther; 2004 Oct; 76(4):290-301. PubMed ID: 15470328
[TBL] [Abstract][Full Text] [Related]
9. Twice-daily dosing of esomeprazole effectively inhibits acid secretion in CYP2C19 rapid metabolisers compared with twice-daily omeprazole, rabeprazole or lansoprazole.
Sahara S; Sugimoto M; Uotani T; Ichikawa H; Yamade M; Iwaizumi M; Yamada T; Osawa S; Sugimoto K; Umemura K; Miyajima H; Furuta T
Aliment Pharmacol Ther; 2013 Nov; 38(9):1129-37. PubMed ID: 24099474
[TBL] [Abstract][Full Text] [Related]
10. Acid-suppressive effects of rabeprazole, omeprazole, and lansoprazole at reduced and standard doses: a crossover comparative study in homozygous extensive metabolizers of cytochrome P450 2C19.
Shimatani T; Inoue M; Kuroiwa T; Xu J; Mieno H; Nakamura M; Tazuma S
Clin Pharmacol Ther; 2006 Jan; 79(1):144-52. PubMed ID: 16413249
[TBL] [Abstract][Full Text] [Related]
11. Esomeprazole 40 mg provides more effective intragastric acid control than lansoprazole 30 mg, omeprazole 20 mg, pantoprazole 40 mg and rabeprazole 20 mg in patients with gastro-oesophageal reflux symptoms.
Röhss K; Lind T; Wilder-Smith C
Eur J Clin Pharmacol; 2004 Oct; 60(8):531-9. PubMed ID: 15349707
[TBL] [Abstract][Full Text] [Related]
12. Effect of esomeprazole and rabeprazole on intragastric pH in healthy Chinese: an open, randomized crossover trial.
Li ZS; Zhan XB; Xu GM; Cheng NN; Liao Z
J Gastroenterol Hepatol; 2007 Jun; 22(6):815-20. PubMed ID: 17565634
[TBL] [Abstract][Full Text] [Related]
13. Esomeprazole-induced healing of gastroesophageal reflux disease is unrelated to the genotype of CYP2C19: evidence from clinical and pharmacokinetic data.
Schwab M; Klotz U; Hofmann U; Schaeffeler E; Leodolter A; Malfertheiner P; Treiber G
Clin Pharmacol Ther; 2005 Dec; 78(6):627-34. PubMed ID: 16338278
[TBL] [Abstract][Full Text] [Related]
14. Clinical impact of CYP2C19 polymorphism on the action of proton pump inhibitors: a review of a special problem.
Klotz U
Int J Clin Pharmacol Ther; 2006 Jul; 44(7):297-302. PubMed ID: 16961157
[TBL] [Abstract][Full Text] [Related]
15. New-generation proton pump inhibitors: overcoming the limitations of early-generation agents.
Robinson M
Eur J Gastroenterol Hepatol; 2001 May; 13 Suppl 1():S43-7. PubMed ID: 11430508
[TBL] [Abstract][Full Text] [Related]
16. Comparison of the effect on intragastric pH of a single dose of omeprazole or rabeprazole: which is suitable for on-demand therapy?
Inamori M; Togawa J; Takahashi K; Yoneda M; Fujisawa N; Iwasaki T; Ozawa Y; Kikuchi T; Muramatsu K; Chiguchi G; Matsumoto S; Kawamura H; Abe Y; Kirikoshi H; Kobayashi N; Sakaguchi T; Takamura T; Nakajima A; Ueno N; Sekihara H
J Gastroenterol Hepatol; 2003 Sep; 18(9):1034-8. PubMed ID: 12911659
[TBL] [Abstract][Full Text] [Related]
17. Influence of cytochrome P450 2C19 genetic polymorphism and dosage of rabeprazole on accuracy of proton-pump inhibitor testing in Chinese patients with gastroesophageal reflux disease.
Lee YC; Lin JT; Wang HP; Chiu HM; Wu MS
J Gastroenterol Hepatol; 2007 Aug; 22(8):1286-92. PubMed ID: 17559380
[TBL] [Abstract][Full Text] [Related]
18. Influence of CYP2C19 pharmacogenetic polymorphism on proton pump inhibitor-based therapies.
Furuta T; Shirai N; Sugimoto M; Nakamura A; Hishida A; Ishizaki T
Drug Metab Pharmacokinet; 2005 Jun; 20(3):153-67. PubMed ID: 15988117
[TBL] [Abstract][Full Text] [Related]
19. Effects of rabeprazole, 20 mg, or esomeprazole, 20 mg, on 24-h intragastric pH and serum gastrin in healthy subjects.
Warrington S; Baisley K; Boyce M; Tejura B; Morocutti A; Miller N
Aliment Pharmacol Ther; 2002 Jul; 16(7):1301-7. PubMed ID: 12144580
[TBL] [Abstract][Full Text] [Related]
20. CYP2C19 genotype and the PPIs--focus on rabeprazole.
Lim PW; Goh KL; Wong BC
J Gastroenterol Hepatol; 2005 Dec; 20 Suppl():S22-8. PubMed ID: 16359346
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]